Skip to main content
Erschienen in: Calcified Tissue International 4/2011

01.10.2011 | Original Research

Forearm Bone Mineral Density in Familial Hypocalciuric Hypercalcemia and Primary Hyperparathyroidism: A Comparative Study

verfasst von: Troels Isaksen, Christian Stoltz Nielsen, Signe Engkjær Christensen, Peter H. Nissen, Lene Heickendorff, Leif Mosekilde

Erschienen in: Calcified Tissue International | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Studies have shown that cancellous bone is relatively preserved in primary hyperparathyroidism (PHPT), whereas bone loss is seen in cortical bone. Familial hypocalciuric hypercalcemia (FHH) patients seem to preserve bone mineral in spite of hypercalcemia and often elevated plasma parathyroid hormone (PTH). The objective of this study was to compare total and regional forearm bone mineral density (BMD) in patients with PHPT and FHH and to examine if differences can be used to separate the two disorders. We included 63 FHH, and 121 PHPT patients in a cross-sectional study. We performed dual-energy X-ray absorptiometry scans of the forearm, hip and lumbar spine and measured a number of biochemical variables. PTH patients had significantly lower Z-scores in all parts of the forearm compared to FHH. This was also the case after adjustment for body mass index. When stratifying for age, gender and PTH, T-scores were still significantly lower in PHPT patients than in FHH patients at the total, the mid and the ultradistal forearm, but not at the proximal 1/3 forearm. In a multiple regression analysis BMD Z-score was lower in PHPT compared to FHH at the total forearm, the mid forearm and the ultradistal forearm but not the proximal forearm when adjusting for biochemical variables including PTH, 1,25(OH)2D and Ca2+. These observations support that inactivating mutations in the CASR gene in bone cells in FHH may protect against forearm bone loss. Differences between the two groups in total or regional forearm BMD were inferior to the calcium/creatinine clearance ratio as a diagnostic tool to separate FHH from PHPT.
Literatur
1.
Zurück zum Zitat Hendy GN, D’Souza-Li L, Yang B, Canaff L, Cole DE (2000) Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 16:281–296PubMedCrossRef Hendy GN, D’Souza-Li L, Yang B, Canaff L, Cole DE (2000) Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 16:281–296PubMedCrossRef
2.
Zurück zum Zitat Raue F, Haag C, Schulze E, Frank-Raue K (2006) The role of the extracellular calcium-sensing receptor in health and disease. Exp Clin Endocrinol Diabetes 114:397–405PubMedCrossRef Raue F, Haag C, Schulze E, Frank-Raue K (2006) The role of the extracellular calcium-sensing receptor in health and disease. Exp Clin Endocrinol Diabetes 114:397–405PubMedCrossRef
3.
Zurück zum Zitat Pidasheva S, D’Souza-Li L, Canaff L, Cole DE, Hendy GN (2004) CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 24:107–111PubMedCrossRef Pidasheva S, D’Souza-Li L, Canaff L, Cole DE, Hendy GN (2004) CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 24:107–111PubMedCrossRef
4.
Zurück zum Zitat Nissen PH, Christensen SE, Heickendorff L, Brixen K, Mosekilde L (2007) Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab 92:4373–4379PubMedCrossRef Nissen PH, Christensen SE, Heickendorff L, Brixen K, Mosekilde L (2007) Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab 92:4373–4379PubMedCrossRef
5.
Zurück zum Zitat Abugassa S, Nordenstrom J, Jarhult J (1992) Bone mineral density in patients with familial hypocalciuric hypercalcaemia (FHH). Eur J Surg 158:397–402PubMed Abugassa S, Nordenstrom J, Jarhult J (1992) Bone mineral density in patients with familial hypocalciuric hypercalcaemia (FHH). Eur J Surg 158:397–402PubMed
6.
Zurück zum Zitat Law WM Jr, Wahner HW, Heath H 3rd (1984) Bone mineral density and skeletal fractures in familial benign hypercalcemia (hypocalciuric hypercalcemia). Mayo Clin Proc 59:811–815PubMed Law WM Jr, Wahner HW, Heath H 3rd (1984) Bone mineral density and skeletal fractures in familial benign hypercalcemia (hypocalciuric hypercalcemia). Mayo Clin Proc 59:811–815PubMed
7.
Zurück zum Zitat Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde L (2009) Skeletal consequences of familial hypocalciuric hypercalcaemia versus primary hyperparathyroidism. Clin Endocrinol (Oxf) 71:798–807CrossRef Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde L (2009) Skeletal consequences of familial hypocalciuric hypercalcaemia versus primary hyperparathyroidism. Clin Endocrinol (Oxf) 71:798–807CrossRef
8.
Zurück zum Zitat Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470PubMedCrossRef Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470PubMedCrossRef
9.
Zurück zum Zitat Mosekilde L (2008) Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1–19CrossRef Mosekilde L (2008) Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1–19CrossRef
10.
Zurück zum Zitat Dempster DW, Muller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JP (2007) Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 41:19–24PubMedCrossRef Dempster DW, Muller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JP (2007) Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 41:19–24PubMedCrossRef
11.
Zurück zum Zitat Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K (2003) Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 88:4655–4658PubMedCrossRef Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K (2003) Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 88:4655–4658PubMedCrossRef
12.
Zurück zum Zitat Chappard C, Houillier P, Paillard M (2001) Bone status in primary hyperparathyroidism. Joint Bone Spine 68:112–119PubMedCrossRef Chappard C, Houillier P, Paillard M (2001) Bone status in primary hyperparathyroidism. Joint Bone Spine 68:112–119PubMedCrossRef
13.
Zurück zum Zitat Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Charles P, Mosekilde L (1997) Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21:93–99PubMedCrossRef Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Charles P, Mosekilde L (1997) Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21:93–99PubMedCrossRef
14.
Zurück zum Zitat Steiniche T, Christiansen P, Vesterby A, Ullerup R, Hessov I, Mosekilde LE, Melsen F (2000) Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone 26:535–543PubMedCrossRef Steiniche T, Christiansen P, Vesterby A, Ullerup R, Hessov I, Mosekilde LE, Melsen F (2000) Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone 26:535–543PubMedCrossRef
15.
Zurück zum Zitat Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598–602PubMedCrossRef Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598–602PubMedCrossRef
16.
Zurück zum Zitat Nordenstrom E, Westerdahl J, Lindergard B, Lindblom P, Bergenfelz A (2002) Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg 26:1463–1467PubMedCrossRef Nordenstrom E, Westerdahl J, Lindergard B, Lindblom P, Bergenfelz A (2002) Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg 26:1463–1467PubMedCrossRef
17.
Zurück zum Zitat Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L (2009) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68:707–715CrossRef Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L (2009) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68:707–715CrossRef
18.
Zurück zum Zitat Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88:3501–3504PubMedCrossRef Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88:3501–3504PubMedCrossRef
19.
Zurück zum Zitat Park SH, Goo JM, Jo CH (2004) Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol 5:11–18PubMedCrossRef Park SH, Goo JM, Jo CH (2004) Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol 5:11–18PubMedCrossRef
20.
Zurück zum Zitat Chappard C, Roux C, Laugier P, Paillard M, Houillier P (2006) Bone status in primary hyperparathyroidism assessed by regional bone mineral density from the whole body scan and QUS imaging at calcaneus. Joint Bone Spine 73:86–94PubMedCrossRef Chappard C, Roux C, Laugier P, Paillard M, Houillier P (2006) Bone status in primary hyperparathyroidism assessed by regional bone mineral density from the whole body scan and QUS imaging at calcaneus. Joint Bone Spine 73:86–94PubMedCrossRef
21.
Zurück zum Zitat Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP, Dempster DW (1990) The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 70:930–938PubMedCrossRef Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP, Dempster DW (1990) The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 70:930–938PubMedCrossRef
22.
Zurück zum Zitat Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW (1991) Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 6(Suppl 2):S85–S89PubMed Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW (1991) Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 6(Suppl 2):S85–S89PubMed
23.
Zurück zum Zitat Silverberg SJ, Shane E, De la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV (1989) Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283–291PubMedCrossRef Silverberg SJ, Shane E, De la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV (1989) Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283–291PubMedCrossRef
24.
Zurück zum Zitat Vogel M, Hahn M, Delling G (1995) Trabecular bone structure in patients with primary hyperparathyroidism. Virchows Arch 426:127–134PubMedCrossRef Vogel M, Hahn M, Delling G (1995) Trabecular bone structure in patients with primary hyperparathyroidism. Virchows Arch 426:127–134PubMedCrossRef
25.
Zurück zum Zitat Alfredson H, Nordstrom P, Lorentzon R (1997) Bone mass in female volleyball players: a comparison of total and regional bone mass in female volleyball players and nonactive females. Calcif Tissue Int 60:338–342PubMedCrossRef Alfredson H, Nordstrom P, Lorentzon R (1997) Bone mass in female volleyball players: a comparison of total and regional bone mass in female volleyball players and nonactive females. Calcif Tissue Int 60:338–342PubMedCrossRef
26.
Zurück zum Zitat Haapasalo H, Kontulainen S, Sievanen H, Kannus P, Jarvinen M, Vuori I (2000) Exercise-induced bone gain is due to enlargement in bone size without a change in volumetric bone density: a peripheral quantitative computed tomography study of the upper arms of male tennis players. Bone 27:351–357PubMedCrossRef Haapasalo H, Kontulainen S, Sievanen H, Kannus P, Jarvinen M, Vuori I (2000) Exercise-induced bone gain is due to enlargement in bone size without a change in volumetric bone density: a peripheral quantitative computed tomography study of the upper arms of male tennis players. Bone 27:351–357PubMedCrossRef
27.
Zurück zum Zitat Fourth international conference on bone measurement (1978) [Proceedings]. AJR Am J Roentgenol 131:539–553 Fourth international conference on bone measurement (1978) [Proceedings]. AJR Am J Roentgenol 131:539–553
28.
Zurück zum Zitat Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, Katsalira K, Lyritis GP (2006) Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 91:1748–1753PubMedCrossRef Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, Katsalira K, Lyritis GP (2006) Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 91:1748–1753PubMedCrossRef
29.
Zurück zum Zitat Bilezikian JP, Rubin M, Silverberg SJ (2006) Asymptomatic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 50:647–656PubMedCrossRef Bilezikian JP, Rubin M, Silverberg SJ (2006) Asymptomatic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 50:647–656PubMedCrossRef
30.
Zurück zum Zitat Engelke K, Libanati C, Liu Y, Wang H, Austin M, Fuerst T, Stampa B, Timm W, Genant HK (2009) Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone 45:110–118PubMedCrossRef Engelke K, Libanati C, Liu Y, Wang H, Austin M, Fuerst T, Stampa B, Timm W, Genant HK (2009) Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone 45:110–118PubMedCrossRef
31.
Zurück zum Zitat Dalle Carbonare L, Ballanti P, Bertoldo F, Valenti MT, Giovanazzi B, Giannini S, Realdi G, Lo Cascio V (2008) Trabecular bone microarchitecture in mild primary hyperparathyroidism. J Endocrinol Invest 31:525–530PubMed Dalle Carbonare L, Ballanti P, Bertoldo F, Valenti MT, Giovanazzi B, Giannini S, Realdi G, Lo Cascio V (2008) Trabecular bone microarchitecture in mild primary hyperparathyroidism. J Endocrinol Invest 31:525–530PubMed
32.
Zurück zum Zitat Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimml DB, Recker R, Lindsay R, Bilezikian JP (1999) On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:1562–1566PubMedCrossRef Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimml DB, Recker R, Lindsay R, Bilezikian JP (1999) On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:1562–1566PubMedCrossRef
33.
Zurück zum Zitat Parfitt AM (1976) The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III of IV parts; PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism. Metabolism 25:1033–1069PubMedCrossRef Parfitt AM (1976) The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III of IV parts; PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism. Metabolism 25:1033–1069PubMedCrossRef
34.
35.
Zurück zum Zitat Yamaguchi T, Chattopadhyay N, Kifor O, Ye C, Vassilev PM, Sanders JL, Brown EM (2001) Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line. Am J Physiol Cell Physiol 280:C382–C393PubMed Yamaguchi T, Chattopadhyay N, Kifor O, Ye C, Vassilev PM, Sanders JL, Brown EM (2001) Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line. Am J Physiol Cell Physiol 280:C382–C393PubMed
36.
Zurück zum Zitat Kameda T, Mano H, Yamada Y, Takai H, Amizuka N, Kobori M, Izumi N, Kawashima H, Ozawa H, Ikeda K, Kameda A, Hakeda Y, Kumegawa M (1998) Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem Biophys Res Commun 245:419–422PubMedCrossRef Kameda T, Mano H, Yamada Y, Takai H, Amizuka N, Kobori M, Izumi N, Kawashima H, Ozawa H, Ikeda K, Kameda A, Hakeda Y, Kumegawa M (1998) Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem Biophys Res Commun 245:419–422PubMedCrossRef
37.
Zurück zum Zitat Marie PJ (2010) The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46:571–576PubMedCrossRef Marie PJ (2010) The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46:571–576PubMedCrossRef
38.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2005) Reduced relative risk of fractures among users of lithium. Calcif Tissue Int 77:1–8PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2005) Reduced relative risk of fractures among users of lithium. Calcif Tissue Int 77:1–8PubMedCrossRef
39.
Zurück zum Zitat Wilting I, de Vries F, Thio BM, Cooper C, Heerdink ER, Leufkens HG, Nolen WA, Egberts AC, van Staa TP (2007) Lithium use and the risk of fractures. Bone 40:1252–1258PubMedCrossRef Wilting I, de Vries F, Thio BM, Cooper C, Heerdink ER, Leufkens HG, Nolen WA, Egberts AC, van Staa TP (2007) Lithium use and the risk of fractures. Bone 40:1252–1258PubMedCrossRef
40.
Zurück zum Zitat Khosla S, Melton J 3rd (2002) Fracture risk in primary hyperparathyroidism. J Bone Miner Res 17(Suppl 2):N103–N107PubMed Khosla S, Melton J 3rd (2002) Fracture risk in primary hyperparathyroidism. J Bone Miner Res 17(Suppl 2):N103–N107PubMed
41.
Zurück zum Zitat Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon W, Riggs B (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707PubMedCrossRef Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon W, Riggs B (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707PubMedCrossRef
42.
Zurück zum Zitat Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed
43.
Zurück zum Zitat Kelly TJ (1990) Bone mineral density reference database for American men and women. J Bone Miner Res 5(Suppl 2):S249 Kelly TJ (1990) Bone mineral density reference database for American men and women. J Bone Miner Res 5(Suppl 2):S249
44.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16:134–141PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16:134–141PubMedCrossRef
Metadaten
Titel
Forearm Bone Mineral Density in Familial Hypocalciuric Hypercalcemia and Primary Hyperparathyroidism: A Comparative Study
verfasst von
Troels Isaksen
Christian Stoltz Nielsen
Signe Engkjær Christensen
Peter H. Nissen
Lene Heickendorff
Leif Mosekilde
Publikationsdatum
01.10.2011
Verlag
Springer-Verlag
Erschienen in
Calcified Tissue International / Ausgabe 4/2011
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-011-9517-x

Weitere Artikel der Ausgabe 4/2011

Calcified Tissue International 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.